HRP20192100T1 - Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe - Google Patents

Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe Download PDF

Info

Publication number
HRP20192100T1
HRP20192100T1 HRP20192100TT HRP20192100T HRP20192100T1 HR P20192100 T1 HRP20192100 T1 HR P20192100T1 HR P20192100T T HRP20192100T T HR P20192100TT HR P20192100 T HRP20192100 T HR P20192100T HR P20192100 T1 HRP20192100 T1 HR P20192100T1
Authority
HR
Croatia
Prior art keywords
synergistic combination
lymphoma
use according
sequence
seq
Prior art date
Application number
HRP20192100TT
Other languages
English (en)
Inventor
Jan Endell
Rainer Boxhammer
Mark Winderlich
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HRP20192100T1 publication Critical patent/HRP20192100T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (15)

1. Sinergistička kombinacija koja sadrži antitijelo specifično za CD19 naznačena time što navedeno antitijelo sadrži HCDR1 područje sa sekvencom SYVMH (SEQ ID NO: 1), HCDR2 područje sa sekvencom NPYNDG (SEQ ID NO: 2), HCDR3 područje sa sekvencom GTYYYGTRVFDY (SEQ ID NO: 3), LCDR1 područje sa sekvencom RSSKSLQNVNGNTYLY (SEQ ID NO: 4), LCDR2 područje sa sekvencom RMSNLNS (SEQ ID NO: 5) i LCDR3 područje sa sekvencom MQHLEYPIT (SEQ ID NO: 6) i ibrutinib, za uporabu u liječenju ne-Hodgkinovog limfoma, kronične limfocitne leukemije i/ili akutne limfoblastne leukemije.
2. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time što antitijelo sadrži varijabilan teški lanac sa sekvencom EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG QGTLVTVSS (SEQ ID NO: 10) i varijabilan laki lanac sa sekvencom
3. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevima 1 ili 2, naznačena time što antitijelo sadrži konstantnu domenu teškog lanca sa sekvencom
4. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što antitijelo sadrži konstantnu domenu lakog lanca sa sekvencom
5. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se navedeno antitijelo specifično za CD19 i ibrutinib primjenjuju odvojeno.
6. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se ibrutinib primjenjuje prije primjene antitijela specifičnog za CD19.
7. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se navedeno antitijelo specifično za CD19 i ibrutinib primjenjuju istovremeno.
8. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se navedeno antitijelo specifično za CD19 i ibrutinib primjenjuju u isto vrijeme, pri čemu su oba lijeka aktivna u pacijentu u isto vrijeme.
9. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, za uporabu u liječenju kronične limfocitne leukemije.
10. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, za uporabu u liječenju akutne limfoblastne leukemije.
11. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, za uporabu u liječenju ne-Hodgkinovog limfoma, pri čemu je ne-Hodgkinov limfom odabran iz grupe koja se sastoji od folikularnog limfoma, limfoma malih limfocita, limfoidnog tkiva povezanog sa sluznicom, marginalne zone, difuznih velikih B stanica, Burkittova i stanica plašta.
12. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom folikularni limfom.
13. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom difuzni limfom velikih B stanica.
14. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom Burkittov limfom.
15. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 11, naznačena time što je ne-Hodgkinov limfom limfom stanica plašta.
HRP20192100TT 2015-05-26 2019-11-22 Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe HRP20192100T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15169124 2015-05-26
EP15196860 2015-11-27
EP16725504.1A EP3302550B1 (en) 2015-05-26 2016-05-25 Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
PCT/EP2016/061744 WO2016189014A1 (en) 2015-05-26 2016-05-25 Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
HRP20192100T1 true HRP20192100T1 (hr) 2020-02-21

Family

ID=56084030

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192100TT HRP20192100T1 (hr) 2015-05-26 2019-11-22 Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe

Country Status (22)

Country Link
US (3) US10617691B2 (hr)
EP (2) EP3302550B1 (hr)
JP (3) JP6916741B2 (hr)
KR (1) KR20180004286A (hr)
CN (2) CN114601931B (hr)
AU (3) AU2016266708B2 (hr)
CA (1) CA2986175A1 (hr)
CY (1) CY1122298T1 (hr)
DK (1) DK3302550T3 (hr)
ES (1) ES2754431T3 (hr)
HK (1) HK1251152B (hr)
HR (1) HRP20192100T1 (hr)
HU (1) HUE046328T2 (hr)
IL (2) IL255377B (hr)
LT (1) LT3302550T (hr)
PL (1) PL3302550T3 (hr)
PT (1) PT3302550T (hr)
RS (1) RS59605B1 (hr)
RU (1) RU2756010C2 (hr)
SI (1) SI3302550T1 (hr)
WO (1) WO2016189014A1 (hr)
ZA (1) ZA201707867B (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN116120454A (zh) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
JP7548587B2 (ja) * 2018-09-07 2024-09-10 アイタブメッド (エイチケイ) リミテッド 二重特異性抗原結合タンパク質及びその使用
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
CA3203587A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2024037594A1 (en) * 2022-08-19 2024-02-22 Beijing Innocare Pharma Tech Co., Ltd. Combination treatment with orelabrutinib and tafasitamab
KR102655236B1 (ko) 2024-01-02 2024-04-08 한화시스템(주) 빔 조향범위 확장 구조를 가지는 저궤도 통신위성 배열안테나

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
DK2718270T3 (da) 2011-06-10 2022-08-01 Merck Patent Gmbh Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
HUE058855T2 (hu) 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
TWI573792B (zh) * 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
JP2015526520A (ja) * 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Itk阻害剤としてのベンズイミダゾール誘導体
WO2014113932A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors

Also Published As

Publication number Publication date
PL3302550T3 (pl) 2020-02-28
JP6916741B2 (ja) 2021-08-11
AU2024201029A1 (en) 2024-03-14
EP3302550B1 (en) 2019-08-28
WO2016189014A1 (en) 2016-12-01
JP2023058502A (ja) 2023-04-25
DK3302550T3 (da) 2019-11-04
HK1251152B (zh) 2020-04-24
LT3302550T (lt) 2019-11-11
RS59605B1 (sr) 2020-01-31
ES2754431T3 (es) 2020-04-17
CN114601931B (zh) 2023-09-01
PT3302550T (pt) 2019-11-26
EP3603672A1 (en) 2020-02-05
US20200206228A1 (en) 2020-07-02
CN114601931A (zh) 2022-06-10
IL255377B (en) 2021-12-01
US20240009196A1 (en) 2024-01-11
IL287433A (en) 2021-12-01
IL255377A (en) 2018-02-28
AU2022202796B2 (en) 2023-11-23
SI3302550T1 (sl) 2020-01-31
US20180153892A1 (en) 2018-06-07
US10617691B2 (en) 2020-04-14
CN107660151A (zh) 2018-02-02
KR20180004286A (ko) 2018-01-10
RU2017143166A (ru) 2019-06-27
JP2021152029A (ja) 2021-09-30
HUE046328T2 (hu) 2020-03-30
RU2017143166A3 (hr) 2019-11-28
CY1122298T1 (el) 2021-01-27
RU2756010C2 (ru) 2021-09-24
EP3302550A1 (en) 2018-04-11
CA2986175A1 (en) 2016-12-01
ZA201707867B (en) 2021-03-31
JP2018516905A (ja) 2018-06-28
CN107660151B (zh) 2022-03-11
AU2016266708A1 (en) 2017-11-16
AU2016266708B2 (en) 2022-02-03
AU2022202796A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
HRP20192100T1 (hr) Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe
HRP20210838T1 (hr) Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe
HRP20210945T1 (hr) Formulacije protutijela anti-cd19
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
HRP20211291T1 (hr) Kombinacije i njihove primjene
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
RU2014103490A (ru) Комбинированная терапия с помощью антитела к cd19 и аналога пурина
HRP20231021T1 (hr) Protutijela anti-cd38 za liječenje akutne limfoblastične leukemije
RU2015110981A (ru) Комбинации и их применение
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
RU2014103492A (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
JP2017507954A5 (hr)
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NZ740221A (en) St2l antagonists and methods of use
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
EA031493B9 (ru) Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
MX2014005996A (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
JP2019533682A5 (hr)
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo